223 related articles for article (PubMed ID: 24037524)
1. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.
Kosari F; Ida CM; Aubry MC; Yang L; Kovtun IV; Klein JL; Li Y; Erdogan S; Tomaszek SC; Murphy SJ; Bolette LC; Kolbert CP; Yang P; Wigle DA; Vasmatzis G
Oncogene; 2014 Jul; 33(29):3776-83. PubMed ID: 24037524
[TBL] [Abstract][Full Text] [Related]
2. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
3. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
[TBL] [Abstract][Full Text] [Related]
4. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
5. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
Fujino K; Motooka Y; Hassan WA; Ali Abdalla MO; Sato Y; Kudoh S; Hasegawa K; Niimori-Kita K; Kobayashi H; Kubota I; Wakimoto J; Suzuki M; Ito T
Am J Pathol; 2015 Dec; 185(12):3164-77. PubMed ID: 26482608
[TBL] [Abstract][Full Text] [Related]
6. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.
Luo SY; Sit KY; Sihoe AD; Suen WS; Au WK; Tang X; Ma ES; Chan WK; Wistuba II; Minna JD; Tsao GS; Lam DC
Lung Cancer; 2014 Aug; 85(2):282-92. PubMed ID: 24976335
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
9. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
[TBL] [Abstract][Full Text] [Related]
11. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
[TBL] [Abstract][Full Text] [Related]
12. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
13. ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.
Miyashita N; Horie M; Mikami Y; Urushiyama H; Fukuda K; Miyakawa K; Matsuzaki H; Makita K; Morishita Y; Harada H; Backman M; Lindskog C; Brunnström H; Micke P; Nagase T; Saito A
Cancer Lett; 2020 Oct; 489():121-132. PubMed ID: 32534174
[TBL] [Abstract][Full Text] [Related]
14. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
15. An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.
Miyashita N; Horie M; Suzuki HI; Yoshihara M; Djureinovic D; Persson J; Brunnström H; Lindskog C; Elfving H; Micke P; Saito A; Nagase T
J Thorac Oncol; 2018 Nov; 13(11):1676-1691. PubMed ID: 30121393
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Michels S; Scheel AH; Scheffler M; Schultheis AM; Gautschi O; Aebersold F; Diebold J; Pall G; Rothschild S; Bubendorf L; Hartmann W; Heukamp L; Schildhaus HU; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Fischer R; Nogovà L; Mattonet C; Hein R; Adams A; Gerigk U; Schulte W; Lüders H; Grohé C; Graeven U; Müller-Naendrup C; Draube A; Kambartel KO; Krüger S; Schulze-Olden S; Serke M; Engel-Riedel W; Kaminsky B; Randerath W; Merkelbach-Bruse S; Büttner R; Wolf J
J Thorac Oncol; 2016 Jan; 11(1):122-7. PubMed ID: 26762747
[TBL] [Abstract][Full Text] [Related]
17. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
18. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
19. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer.
Sasaki H; Shimizu S; Tani Y; Maekawa M; Okuda K; Yokota K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Cancer Med; 2012 Aug; 1(1):68-75. PubMed ID: 23342255
[TBL] [Abstract][Full Text] [Related]
20. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
